Erlotinib (Tarceva) for advanced non-small cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2005年 / 47卷 / 1205期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [41] Erlotinib in the treatment of advanced non small cell lung cancer Comment
    Kowalski, Dariusz M.
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G45 - G45
  • [42] Erlotinib therapy in advanced non small-cell lung cancer
    Gazdulska, Joanna
    Bryl, Maciej
    Ramlau, Rodryg
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G42 - G45
  • [43] Erlotinib for the treatment of brain metastases in non-small cell lung cancer
    Brower, Jeffrey V.
    Robins, H. Ian
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 1013 - 1021
  • [44] Comparison of erlotinib (Tarceva™) versus gefitinib (Iressa®) as the second line therapy for the treatment of advanced non-small cell lung cancer patients: a randomized phase II trial
    Uhm, Ji Eun
    Sun, Jong Mu
    Lee, Soo Hyeon
    Kong, Jee Hyun
    Yun, Jin A.
    Lee, Sang Mi
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S292 - S292
  • [45] MicroRNA markers for erlotinib resistance in non-small cell lung cancer
    Nelson, Kristen
    Ranade, Aarati
    Kashey, Trevor
    Kingsley, Chris
    Weiss, Glen
    CANCER RESEARCH, 2009, 69
  • [46] Cutaneous complications of erlotinib in the treatment of non-small cell lung cancer
    Preda, V.
    Mann, S.
    Lee, S.
    HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2008, 16 (03): : 133 - 141
  • [47] Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
    Li, Tianhong
    Lara, Primo N., Jr.
    Mack, Philip C.
    Perez-Soler, Roman
    Gandara, David R.
    CURRENT DRUG TARGETS, 2010, 11 (01) : 85 - 94
  • [48] Erlotinib: a new therapeutic approach for non-small cell lung cancer
    Bonomi, P
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (08) : 1395 - 1401
  • [49] Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case
    Gridelli, C.
    Rossi, A.
    Maione, P.
    Ferrara, C.
    Del Gaizo, F.
    Nicolella, D.
    Guerriero, C.
    Colantuoni, G.
    TARGETED ONCOLOGY, 2006, 1 (01) : 56 - 58
  • [50] Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity
    Ardavanis, Alexandros
    Koumna, Stella
    Fragos, Ioannis
    Malliou, Savvoula
    Kyriakou, Flora
    Mantzaris, Ioannis
    Scorilas, Andreas
    Rigatos, Gerassimos
    ANTICANCER RESEARCH, 2008, 28 (4C) : 2409 - 2415
12345